Home » News » CROs/Service Providers » Quintiles Invests in Biotech

Quintiles Invests in Biotech

Friday, January 12, 2007

Quintiles Transnational’s strategic partnering unit, NovaQuest, funded a total of $342 million in 16 investments into emerging biotech companies. Quintiles will also provide marketing expertise, strategic development and possibly product development and commercialization. The unit of NovaQuest charged with funding emerging biotech companies is called eBio.

C.G. ‘Chip’ Gillooly, NovaQuest’s global vice president of eBio. said there were three things that are currently driving the booming biotech sector today:

“First, biotech’s continued progress in developing promising new medicines.

Second, private capital markets continue to value these companies more favorably than the global public equities markets, thereby altering investor exit strategies.

Third, the value NovaQuest brings – the experience and intellectual capital necessary to advance experimental programs, non-dilutive financing, alternatives to premature out-licensing and access to Quintiles’ global development and commercialization resources.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!